Highlights
- Market Cap
- $114.38M
- Enterprise Value
- $102.89M
- EPS (TTM)
- -$0.39
- Gross Profit (TTM)
- -$33.70K
- EBITDA (TTM)
- -$31.64M
- Year Range
- $0.77 - $1.59
- ROA (TTM)
- -249.38%
- ROE (TTM)
- -337.72%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Cardiol Therapeutics Inc Class A, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Cardiol Therapeutics Inc Class A (CRDL) has returned 41.54% so far this year and 39.20% over the past 12 months.
Cardiol Therapeutics Inc Class A
- 1D
- 10.66%
- 1M
- 32.35%
- YTD
- 41.54%
- 6M
- 26.17%
- 1Y
- 39.20%
- 3Y*
- 40.45%
- 5Y*
- -17.40%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jan 15, 2019, CRDL's average daily return is +0.09%, while the average monthly return is +0.82%. At this rate, your investment would double in approximately 7.1 years.
Historically, 45% of months were positive and 55% were negative. The best month was Feb 2024 with a return of +68.9%, while the worst month was Nov 2021 at -44.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, CRDL closed higher 45% of trading days. The best single day was Feb 15, 2024 with a return of +42.3%, while the worst single day was Nov 3, 2021 at -25.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.33% | 7.29% | 32.35% | 41.54% | |||||||||
| 2025 | 10.16% | -18.44% | -15.67% | 13.43% | 13.64% | 8.80% | 9.56% | -27.52% | -0.93% | 5.61% | -7.08% | -9.16% | -25.48% |
| 2024 | 44.69% | 68.85% | -12.14% | 11.05% | 30.35% | -22.90% | 6.93% | -10.19% | 2.06% | -9.09% | -10.00% | -20.99% | 51.80% |
| 2023 | 38.10% | -24.69% | -8.13% | 27.15% | 8.80% | 32.03% | 21.35% | 1.85% | -18.64% | -7.26% | 10.42% | -8.00% | 65.33% |
| 2022 | -0.00% | -9.19% | -8.93% | -10.46% | -2.19% | -1.49% | 0.00% | -15.15% | -8.04% | -41.86% | -13.94% | -1.03% | -72.43% |
| 2021 | 12.84% | 41.87% | 0.29% | -1.43% | -21.16% | -11.76% | -6.25% | 66.22% | 10.96% | -12.77% | -44.75% | -7.50% | -15.14% |
Benchmark Metrics
Cardiol Therapeutics Inc Class A has an annualized alpha of 6.09%, beta of 1.19, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since January 16, 2019.
- This stock participated in 165.60% of S&P 500 Index downside but only 70.61% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 6.09%
- Beta
- 1.19
- R²
- 0.07
- Upside Capture
- 70.61%
- Downside Capture
- 165.60%
Return for Risk
Risk / Return Rank
CRDL ranks 60 for risk / return — better than 60% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cardiol Therapeutics Inc Class A (CRDL) and compare them to a chosen benchmark (S&P 500 Index).
| CRDL | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.54 | 0.90 | -0.35 |
Sortino ratioReturn per unit of downside risk | 1.30 | 1.39 | -0.09 |
Omega ratioGain probability vs. loss probability | 1.16 | 1.21 | -0.05 |
Calmar ratioReturn relative to maximum drawdown | 1.02 | 1.40 | -0.38 |
Martin ratioReturn relative to average drawdown | 1.55 | 6.61 | -5.05 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore CRDL risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cardiol Therapeutics Inc Class A. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cardiol Therapeutics Inc Class A was 92.71%, occurring on Apr 5, 2023. The portfolio has not yet recovered.
The current Cardiol Therapeutics Inc Class A drawdown is 78.19%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -92.71% | Feb 25, 2019 | 1037 | Apr 5, 2023 | — | — | — |
| -9.26% | Feb 5, 2019 | 3 | Feb 7, 2019 | 7 | Feb 19, 2019 | 10 |
| -1.86% | Jan 23, 2019 | 1 | Jan 23, 2019 | 2 | Jan 29, 2019 | 3 |
| -0.2% | Jan 17, 2019 | 1 | Jan 17, 2019 | 1 | Jan 18, 2019 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cardiol Therapeutics Inc Class A over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cardiol Therapeutics Inc Class A is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CRDL in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, CRDL has a P/B value of 12.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |